0.87
+0.011(+1.28%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.85 |
| Day High | 0.92 |
| Day Low | 0.83 |
| 52-Week High | 108 |
| 52-Week Low | 0.71 |
| Volume | 570,766 |
| Average Volume | 1.82M |
| Market Cap | 5.1M |
| PE | -0.04 |
| EPS | -24.24 |
| Moving Average 50 Days | 2.87 |
| Moving Average 200 Days | 8.96 |
| Change | 0.01 |
If you invested $1000 in Salarius Pharmaceuticals, Inc. (SLRX) 10 years ago, it would be worth $0 as of December 05, 2025 at a share price of $0.871. Whereas If you bought $1000 worth of Salarius Pharmaceuticals, Inc. (SLRX) shares 5 years ago, it would be worth $0.24 as of December 05, 2025 at a share price of $0.871.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT’
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
GlobeNewswire Inc.
Nov 19, 2025 7:42 PM GMT
Company has pro forma cash of approximately $14 million following recent public offeringHOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
GlobeNewswire Inc.
Nov 13, 2025 1:45 PM GMT
Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and